DONALD E. BOBO JR - 17 May 2021 Form 4 Insider Report for Edwards Lifesciences Corp (EW)

Role
CVP,Strategy/Corp Development
Signature
Linda J. Park, Attorney-in-Fact
Issuer symbol
EW
Transactions as of
17 May 2021
Net transactions value
-$851,050
Form type
4
Filing time
19 May 2021, 16:30:40 UTC
Previous filing
12 May 2021
Next filing
14 Jun 2021
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction EW Common Stock Options Exercise $0 +15,750 +31% $0.000000 65,885 17 May 2021 Direct F1
transaction EW Common Stock Tax liability $152,222 -1,701 -2.6% $89.49 64,184 17 May 2021 Direct
transaction EW Common Stock Tax liability $698,827 -7,809 -12% $89.49 56,375 17 May 2021 Direct
holding EW Common Stock 38,158 17 May 2021 401(k) F2
holding EW Common Stock 123,820 17 May 2021 By Trust

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction EW Performance Rights Options Exercise $0 -15,750 -100% $0.000000* 0 17 May 2021 Common Stock 15,750 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 On May 17, 2018, the Reporting Person was granted a target number of shares covered by restricted stock units with performance-based vesting requirements over a three-year performance period. On May 3, 2021, the Compensation Committee of the Board of Directors determined that 175% of the target number of shares would vest as of May 17, 2021, and the actual number of shares vested are reflected on this Form 4.
F2 Reflects shares represented on the most recent statement of the Issuer's 401(k) Plan Administrator.

Remarks:

This Form 4 reflects changes in beneficial ownership only; it does not identify other securities of the Issuer beneficially owned by the Reporting Person.